Prevalence and correlates of cryptococcal antigen positivity among AIDS patients — United States, 1986-2012

Morbidity and Mortality Weekly Report

Volumn , Issue 27, 2014, Pages 585-587

  McKenney, Jennie ^a   Smith, Rachel M ^b   Chiller, Tom M ^b   Detels, Roger ^a   French, Audrey ^c   Margolick, Joseph ^d   Klausner, Jeffrey D ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c Jr Hospital of Cook County   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGUS ANTIGEN;

ADULT; AGED; AIDS RELATED COMPLEX; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS; ETHNIC GROUP; FEMALE; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; RISK FACTOR; STATISTICS; UNITED STATES; YOUNG ADULT;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, FUNGAL; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CRYPTOCOCCUS; ETHNIC GROUPS; FEMALE; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; PREVALENCE; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84903945854     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23:525-30.
2. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002;16:1031-8.
3. Lindsley M, Mekha N, Baggett H, et al. Evaluation of newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 2011;53:321-5.
4. Smith RM, Nguyen TA, Ha HTT, et al. Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program—Vietnam. PLoS ONE 2013;8:e62213.
5. Osazuwa F, Dirisu JO, Okuonghae PE, Ugbebor O. Screening for cryptococcal antigenemia in anti-retroviral naive AIDS patients in Benin City, Nigeria. Oman Med J 2012;27:228-31.
6. Liechty C, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007:12;929-35.
7. Holmquist L, Russo A, Elixhauser A. Meningitis-related hospitalizations in the United States, 2006. Statistical brief no. 57, Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project; 2008. Available at http://www.ncbi.nlm.nih.gov/books/nbk56046.
8. Meya D, Manabe Y, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count ≤100 cells/µl who start HIV therapy in resource-limited settings. Clin Infect Dis 2010;51:448-55.
9. Jarvis JN, Harrison TS, Lawn SD, Meintjes G, Wood R, Cleary S. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS ONE 2013;8:1-10.
10. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 2013;58(1):e1-34.